Abstract:Editorial Office Translational Cancer Research Submitted Oct 09, 2023. Accepted for publication Dec 12, 2023. Published online Jan 24, 2024. doi: 10.21037/tcr-2023-09 Erratum to: Transl Cancer Res 2020;9:763-73. In the February 2020 issue of Translational Cancer Research , the paper titled "High-mobility group A1 (HMGA1) gene expressions in various colorectal cancer cell lines and correlation with prognosis" (1), was published with some errors in Figure 4D and the description of the Figure 4 in the "Results" section. The reason is that the scatterplot is incorrectly named. In the "Results" section, the description of the Figure 4 and the whole Figure 4 should be corrected as below (the figure legend remains intact): We analyzed the HMGA1 expression level in kidney papillary cell carcinoma (pRCC) and kidney clear cell carcinoma (ccRCC). We found that HMGA1 expression level correlated with the clinical overall survival time of patients. The data showed that the lower expression HMGA1 group had a significantly higher (P<0.05) ten-year survival rate than the high expression group ( Figure 4A,4C ). We also analyzed the expression level of HMGA1 in kidney tumor tissues and matched normal tissues; the analysis indicated a high expression of HMGA1 in pRCC tissues in contrast to normal tissues (P<0.05) ( Figure 4B ). Conversely, ccRCC displayed an opposing pattern ( Figure 4D ). Emerging evidence suggests that HMGA1 is higher expressed in ccRCC tissues than normal tissues, especially in metastatic tumor tissues and high-grade RCC (13-16), Chi et al. identified HMGA1 have promote the metastasis of ccRCC via Wnt signaling pathways (17). Several factors might explain the observed reduced HMGA1 expression in our ccRCC: (I) potential limitations in enrollment within TCGA database, possibly influenced by population biases and a constrained patient cohort (18); (II) the scatter plot delineates the disparities in gene expression between cancer and normal tissues, primarily reflecting the variations arising during tumorigenesis. Concurrently, survival prognosis analysis stratifies HMGA1 gene expression in cancer tissues into higher and lower cohorts, subsequently investigating the implications of HMGA1 in the malignancy progression. Notably, RCC exhibits a comparatively favorable prognosis, The 5-year survival of RCC patients with partial nephrectomy was 99.2% for Whites and 93.8% for Blacks (19,20), suggesting RCC tissue is relatively mature differentiation and the potential for lower HMGA1 expression within the tumor and higher expression in the adjacent normal tissues; (III) concerning HMGA1 protein expression, it's pivotal to recognize that proteins serve as the primary functional entities in cellular processes. In the context of ccRCC, it remains uncertain whether HMGA1 mRNA undergoes complete translation to produce corresponding proteins, and if these translated proteins exhibit stability without undergoing degradation pathways, such as ubiquitination. In summary, delineating the expression and function of HMGA1 in ccRCC requires integration with relevant research results and targeted cellular assays. Due to the addition of new references, the references list and in-text citations should be renumbered. The updated reference should be updated as follows: 1. Sumter TF, Xian L, Huso T, et al. The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. Curr Mol Med 2016;16:353-93. 2. Wang Y, Hu L, Zheng Y, et al. HMGA1 in cancer: Cancer classification by location. J Cell Mol Med 2019;23:2293-302. 3. Frasca F, Rustighi A, Malaguarnera R, et al. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 2006;66:2980-9. 4. Zhong J, Liu C, Zhang QH, et al. TGF-beta1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion. Int J Oncol 2017;50:1567-78. 5. Xian L, Georgess D, Huso T, et al. HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche. Nat Commun 2017;8:15008. 6. Resar L, Chia L, Xian L. Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression. Cancer Res 2018;78:1890-7. 7. Liang L, Li X, Zhang X, et al. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. Gastroenterology 2013;144:624-35.e4. 8. Chandrasekaran KS, Sathyanarayanan A, Karunagaran D. MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells. Br J Cancer 2016;115:741-51. 9. Chiefari E, Foti DP, Sgarra R, et al. Transcriptional Regulation of Glucose Metabolism: The Emerging Role of the HMGA1 Chromatin F -Abstract Truncated-

High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential

Decoding high mobility group A2 protein expression regulation and implications in human cancers

HMGA1 As a Potential Prognostic and Therapeutic Biomarker in Breast Cancer

Multiple functions of HMGB1 in cancer

HMGA2 Promotes Resistance Against Paclitaxel by Targeting the P53 Signaling Pathway in Colorectal Cancer Cells

HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Data from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

HMGB1 in Cancer: Good, Bad, or Both?

Hmga2 Sustains Self-Renewal and Invasiveness of Glioma-Initiating Cells

The mechanism of high mobility group box-1 protein and its bidirectional regulation in tumors

HMGB1 in health and disease

Overexpression Of Hmga2 Promotes Metastasis And Impacts Survival Of Advanced Colorectal Cancers

Emerging roles for HMGA2 in colorectal cancer

High Mobility Group A1 Chromatin Regulators Drive Regenerative Capacity during Stress Hematopoiesis through Modulation of TNF-α and Aging Transcriptional Networks

Erratum to hypofractionation in prostate cancer radiotherapy

HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer

Targeting HMGB1: an Available Therapeutic Strategy for Breast Cancer Therapy

Biological functions and theranostic potential of HMGB family members in human cancers

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

Abstract 6450: High mobility group protein 2 (HMGA2) is highly expressed in a broad range of human cancers

Effects of HMGA2 on the biological characteristics and stemness acquisition of gastric cancer cells